Ernexa Therapeutics Inc. (ERNA) stock
Close on Nov 11, 2026Market cap $3.15MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $3.15M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.72
- Dividend yield
- –
- Free cash flow yield
- -341.34%
Fundamentals
- Net income
- -$13.96M
- EPS, diluted
- -$2.24
- Free cash flow
- -$10.75M
- Book value per share
- $2.79
- Diluted shares
- 2M
Trading
- Previous close
- $2.01
- Open
- $2.05
- Day's range
- $1.90 – $2.05
- Volume
- 9,815
- Average volume (20 days)
- 16,053
- Beta (5 years)
- 1.59
- 52-week range
- $1.74 – $41.99
- RSI (14 days)
- 37.3
- Volatility (1 year)
- 152.2%
- Relative volume
- 0.03×
- WACC
- 12.8%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ERNA | S&P 500 | Difference | ERNA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -19.6% | -2.4% | −17.2 pts | ||
| 3 months | -56.0% | -1.2% | −54.9 pts | ||
| Year to date | -93.6% | +12.3% | −105.9 pts | ||
| 1 year | -95.1% | +12.4% | −107.6 pts | ||
| 3 years | -99.6% | +78.8% | −178.4 pts | -83.7% | +21.4% |
| 5 years | -100.0% | +75.2% | −175.2 pts | -87.5% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -66.6% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ernexa Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- News
About Ernexa Therapeutics
Pharmaceutical Preparations
Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC therapy company focused on developing cell therapies for cancer, autoimmune diseases, and rare conditions. The company utilizes induced pluripotent stem cell-derived mesenchymal stem cells engineered to deliver therapeutic agents directly to disease sites. Its lead candidate, ERNA-101, is designed to secrete interleukins directly into the tumor microenvironment for conditions like ovarian cancer. In addition, the company develops ERNA-201, an anti-inflammatory cytokine-secreting therapy aimed at autoimmune disorders such as rheumatoid arthritis.
Company profile, executives and historyErnexa Therapeutics stock: common questions
What is Ernexa Therapeutics's stock price?
ERNA closed at $1.93 on Nov 11, 2026, down 3.98% on the day. Over the past 52 weeks it traded between $1.74 and $41.99.
What is Ernexa Therapeutics's market cap?
Ernexa Therapeutics was worth $3.15M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ERNA's P/E ratio?
Ernexa Therapeutics lost money over fiscal 2025 (diluted EPS -$2.24), so it has no meaningful P/E ratio.
Does Ernexa Therapeutics pay a dividend?
No. Ernexa Therapeutics has not paid a cash dividend over the last twelve months.
How has ERNA stock performed over the past year?
Including dividends, ERNA returned -95.1% over the past year, against +12.4% for the S&P 500.
Who are Ernexa Therapeutics's competitors?
Companies most similar to Ernexa Therapeutics by business, industry and size include VCNX, XCUR, RLYB, RNAC, RGBP.
See a number that looks wrong?